You are here

  • Home
  • Archive
  • Volume 99, Issue 3
  • Performance of the first commercial dual resistance assay, AmpliSens Mycoplasma genitalium-ML/FQ-Resist-FL, for detection of potential macrolide and quinolone resistance-associated mutations and prevalence of M. genitalium resistance mutations in St. Pet…

Citation Tools

Article menu
Short report
Performance of the first commercial dual resistance assay, AmpliSens Mycoplasma genitalium-ML/FQ-Resist-FL, for detection of potential macrolide and quinolone resistance-associated mutations and prevalence of M. genitalium resistance mutations in St. Petersburg, Russia

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Shipitsyna E, Khusnutdinova T, Budilovskaya O, et al
Performance of the first commercial dual resistance assay, AmpliSens Mycoplasma genitalium-ML/FQ-Resist-FL, for detection of potential macrolide and quinolone resistance-associated mutations and prevalence of M. genitalium resistance mutations in St. Petersburg, Russia
Sexually Transmitted Infections 2023;99:191-194.